Search

Sparsentan

[A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT₁R antagonist, and biphenylsulfonamide, an ET<sub … Sparsentan is a dual antagonist of the endothelin type A receptor (ET_AR) and the angiotensin II (Ang II) type 1 receptor (AT₁R) with a similar affinity for both (9.3 nM for ET<sub

DL-alpha tocopheryl acetate

Edrophonium

A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.

Teclistamab

[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.

Golodirsen

This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of

Taurine

Taurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs. It plays important role in essential biological processes. … [A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat.

Polihexanide

[A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite. … [L53003] It was initially approved in August of 2024, and is the first and only approved therapy to treat patients with _Acanthamoeba_ keratitis. [L53143]

Gadopentetic acid

(From Martindale, The Extra Pharmacopoeia, 30th ed, p706) … A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs.

Brilliant blue G

Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures. … It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]

Empagliflozin

in 2014. … Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart